• ქართული
  • English
  • Shire faces criticism on CEO pay policy as crunch week looms

    LONDON (Reuters) – Shire , the $47 billion rare disease drugmaker being stalked by Japan’s Takeda Pharmaceutical , faces fresh criticism over its executive pay policy from a leading investor advisory group as a crunch week approaches.

    Market Quotes by TradingView